Molecular mechanism of CHRDL1-mediated X-linked megalocornea in humans and in Xenopus model by Pfirrmann, Thorsten et al.
OR I G INA L ART I C L E
Molecular mechanism of CHRDL1-mediated X-linked
megalocornea in humans and in Xenopusmodel
Thorsten Pﬁrrmann1,†, Denise Emmerich4,7,†, Peter Ruokonen5,
Dagmar Quandt2, Renate Buchen8, Björn Fischer-Zirnsak4,7, Jochen Hecht4,6,
Peter Krawitz4, Peter Meyer10, Eva Klopocki11, Sigmar Stricker7,12,
Ekkehart Lausch9, Barbara Seliger2, Thomas Hollemann1, Thomas Reinhard8,
Claudia Auw-Haedrich8, Bernhard Zabel9, Katrin Hoffmann3
and Pablo Villavicencio-Lorini3,*
1Institute of Physiological Chemistry, 2Institute ofMedical Immunology and 3Institute of HumanGenetics, Martin
Luther University Halle-Wittenberg, 06112 Halle, Saale, Germany, 4Institute of Medical and Human Genetics,
5Department of Ophthalmology and 6Berlin-Brandenburg Center for Regenerative Therapies, Charité
Universitätsmedizin Berlin, 13353 Berlin, Germany, 7Development and Disease Group, Max-Planck-Institute for
Molecular Genetics, 14195 Berlin, Germany, 8Department of Ophthalmology and 9Center for Pediatrics and
AdolescentMedicine, University Hospital of Freiburg, 79106 Freiburg, Germany, 10Department of Ophthalmology,
University of Basel, 4056 Basel, Switzerland, 11Institute of Human Genetics, Biocenter, Julius-Maximilians
University Würzburg, 97074 Würzburg, Germany and 12Institute for Chemistry and Biochemistry, Freie
Universität Berlin, 14195 Berlin, Germany
*Towhom correspondence should be addressed at: Institute of Human Genetics, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112 Halle
(Saale), Germany. Tel: +49 3455574437; Fax: +49 3455574701; Email: pablo.lorini@uk-halle.de
Abstract
Chordin-Like 1 (CHRDL1) mutations cause non-syndromic X-linked megalocornea (XMC) characterized by enlarged anterior eye
segments.Mosaic corneal degeneration, presenile cataract and secondary glaucomaare associatedwithXMC. Beside thatCHRDL1
encodes Ventroptin, a secreted bone morphogenetic protein (BMP) antagonist, the molecular mechanism of XMC is not well
understood yet. In a family with broad phenotypic variability of XMC, we identiﬁed the novel CHRDL1 frameshift mutation
c.807_808delTC [p.H270Wfs*22] presumably causing CHRDL1 loss of function. Using Xenopus laevis as model organism, we
demonstrate that chrdl1 is speciﬁcally expressed in the ocular tissue at late developmental stages. The chrdl1 knockdown directly
resembles the human XMC phenotype and conﬁrms CHRDL1 deﬁciency to cause XMC. Interestingly, secondary to this bmp4 is
down-regulated in the Xenopus eyes. Moreover, phospho-SMAD1/5 is altered and BMP receptor 1A is reduced in a XMC patient.
Together, we classify these observations as negative-feedback regulationdue to the deﬁcient BMPantagonism inXMC.As CHRDL1
is preferentially expressed in the limbal stem cell niche of adult human cornea, we assume that CHRDL1 plays a key role in cornea
homeostasis. In conclusion, we provide novel insights into the molecular mechanism of XMC as well as into the speciﬁc role of
CHRDL1during corneaorganogenesis, amongothers by the establishment of theﬁrst XMC in vivomodel.We show that unravelling
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monogenic cornea disorders like XMC—with presumably disturbed cornea growth and differentiation—contribute to the
identiﬁcation of potential limbal stem cell niche factors that are promising targets for regenerative therapies of corneal injuries.
Introduction
X-linkedmegalocornea (XMC) [MIM309300]manifests asan inborn
defect of the anterior eye segment characterized by a corneal
diameter larger than 12.5 mm and a deep anterior eye chamber.
XMC is therefore termed also anterior megalophthalmos and
occurs without elevated intraocular pressure (IOP) (1,2). It is an
important differential diagnosis for primary congenital glaucoma
(IOP-associated buphthalmos) that leads to a high risk of vision
loss and, thus, needs a fast diagnostic clariﬁcation and prompt
treatment (3). Furthermore, XMC is classiﬁed as non-syndromic
and has to be distinguished from megalocornea in the context of
syndromes, e.g. neonatal Marfan syndrome or megalocornea-
mental-retardation (MMR) syndrome [MIM249310] (4,5). Usually,
XMC patients have mild to moderate myopia and some complain
of photophobia and iridodonesis due to iris hypoplasia. Additional
ocular anomalies can be arcus lipoides, mosaic corneal degener-
ation,pigment dispersionalong the innercorneal surface (Kruken-
berg’s spindle), cataract and lens dislocation (2). Although the IOP
is primarily normal,megalocorneamight predispose to secondary
glaucoma due to a widened ciliary body and a potential pigment
deposition in the trabecular meshwork (6,7).
Different mutations in the Chordin-Like 1 (CHRDL1) gene have
been identiﬁed as the disease causing genetic alteration in XMC
(3,8,9). The initial ﬁnding was a 240 kb microdeletion on Xq23
encompassing the CHRDL1 gene (9). Sequence analysis of further
patients with megalocornea revealed missense, nonsense and
frameshift mutations in the CHRDL1 gene. CHRDL1 encodes the
protein Ventroptin, which is a bone morphogenetic protein 4
(BMP4) antagonist (10). As a member of the regulatory network
of transforming growth factor-beta (TGFβ) signaling, Ventroptin
is involved in cell fate determination as well as in cell differenti-
ation. CHRDL1 is expressed in the anterior eye segment (cornea,
lens, trabecular meshwork) and in the retina, starting in embry-
onic development and lasting into adulthood (9,10). It is also
differentially expressed in fetal brain regions, with highest ex-
pression in the cerebellum and the neocortex (9). Overexpression
experiments in embryonic chick retina showed a role of Ventrop-
tin in patterning of retinotectal projections (10). In contrast, pre-
sumed loss of function mutations in humans revealed only mild
cone system dysfunction in retinal electrophysiology and inter-
hemispheric asymmetry in visual evoked potentials in one sub-
ject with a microdeletion encompassing the 3′ end of CHRDL1
(9). Although focal white matter volume reductions could be
found in some patients with megalocornea, no clinical correlate
was observed in the reported patients so far (9). Recently, in one
patient, a CHRDL1missense variant has been detected in associ-
ation with Neuhäuser syndrome, also known as MMR syndrome
[MIM249310]. The authors postulate that this CHRDL1 variant
accounts for the eye phenotype and that the MMR syndrome, in
some cases, might be di- or multigenic (3).
In the present study, we report on a novel CHRDL1 frameshift
mutation in a family with XMC. Moreover, we investigated the
molecular mechanism underlying XMC and its phenotypic vari-
ability. By a knockdown approach, using Xenopus laevis (Xl) as the
ﬁrst model organism for XMC, we characterized the impact of
CHRDL1 deﬁciencyon eye development. Furthermore, we revealed
the inﬂuence on BMP signaling in Humans and Xenopus. Finally,
our data suggest that CHRDL1 (Ventroptin) is very likely a novel
limbal stem cell niche factor of the adult human cornea. These
ﬁndings could contribute to regenerative approaches for the treat-
ment of corneal lesions, as advances in cornea regeneration con-
cepts by targeting limbal stem cell niche factors are becoming
reasonable therapeutic options for allogenic transplantation
(11,12).
Results
XMC shows a broad intrafamilial phenotypic variability
regarding biometric abnormalities and associated ocular
anomalies
The index patient (IV-1), ﬁrst son of non-consanguineoushealthy
parents, was born at 40 weeks’ gestation after uncomplicated
pregnancy with remarkably large eyes reminding of buphthal-
mos (Fig. 1A). Instant diagnostic effortsweremade to exclude pri-
mary congenital glaucoma and to prevent visual loss of the
patient. However, this suspected diagnosis was discarded due
to normal IOP. Since no other organ anomalies were detected, a
syndromic condition seemed not to be likely. In follow-up exam-
inations, no progression of the eye phenotypewas noted and the
patient developed age-based with regard to motor and mental
function.
The family history of the patient was positive for enlarged
eyes and pedigree analysis suggested a X-chromosomal reces-
sive inheritance. Four affected males related to each other
by obligate carrier females could be identiﬁed and no male-
to-male transmission was observed (Fig. 1B). Altogether, the
clinical history of our index patient IV-1 and the pedigree ana-
lysis enabled us to diagnose non-syndromic XMC, a rare genetic
eye disorder. The deceased great-grandfather I-1 of patient IV-1
had been the ﬁrst family member with obvious XMC phenotype.
Moreover, he had undergone bilateral cataract surgery at age of
∼56 years and had developed loss of corneal transparency at age
of 85 years probably due to decompensation of corneal endothe-
lium. Furthermore, he had a restricted peripheral vision ﬁeld on
both sides probably due to glaucoma, but retrospectively IOP
values and optic nerve ﬁndings were not available to verify
this assumption. Consistent with the X-chromosomal recessive
inheritance, none of his sons and daughters was described as
being affected. From the second, third and fourth generation
of our study family, we were able to perform ophthalmic inves-
tigations of two further affected males (III-5, III-8), besides the
index patient IV-1, who was by now 14 years old, and some of
the healthy brothers (III-3, IV-2) as well as obligate carrier
females (II-2, III-1).
The patients IV-1 and III-5 showed spherical refraction anom-
alies on both eyes ranging from −1.5 to −2.5 dioptres revealing
mild myopia. Horizontal corneal diameters of these patients
were at 16 mm and 14.5 mm, whereas the corneal diameters of
their unaffected brothers III-3 and IV-2 were normal at 12 mm
(normal range 11–12.5 mm), respectively (Fig. 1C). The lateral cor-
neal proﬁles of the affected males III-5, III-8 and IV-1 appeared
pre-bulged. Although the index patient IV-1 showed a dome-
shaped cornea, the lateral aspects of the corneas of III-5 and
III-8 appeared to be keratoconus-like. The obligate carrier
females II-2 and III-1 as well as the unaffected male sibling IV-2
of the index patient IV-1 revealed ﬂat corneas (Fig. 1D).
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By optical interferometry, we determined elevated ratios of
anterior chamber (AC) depth versus axial length (AL) being at
0.26 in patient IV-1 and 0.20 in patient III-5 (Fig. 2E). In contrast,
the AC/AL ratios in the unaffected relatives ranged from 0.13 to
0.16. Slit lamp examinations conﬁrmed a very deep anterior eye
chamber of patient IV-1 compared with his unaffected brother
IV-2 (Fig. 2C and D).
Consistent with a non-progressive isolated anterior mega-
lophthalmos, an underlying glaucoma could be excluded in pa-
tient IV-1 once again at the age of 14 years. His IOP was not
elevated (Fig. 2I) nor did the Heidelberg Retina Tomography
(HRT) confocal laser scanning display an pathologic cupping of
the optic nerve head (Fig. 2G and H). Corneal pachymetry indi-
cated a reduced corneal thickness up to 350 µm at the corneal
apex of patient IV-1. The corneal apex thickness of patient III-5
was decreased up to 405 µm in comparison with his unaffected
brother III-3, showing 471 µm (Fig. 2F). In addition, patient III-8
had also a reduced corneal thickness, but despite this, he was
treated for myopia by laser-assisted surface ablation elsewhere
and he suffered from severe pain postoperatively. Although pa-
tient IV-1 exhibited the most apparent anterior megalophthal-
mos in comparison with the other affected males, he did not
have further ocular anomalies, e.g. congenital cataract. Instead,
XMC-associated complications were reported in the patients
I-1, III-5 and III-8: as mentioned before, patient I-1 underwent
cataract surgery early in his ﬁfth decade of life, whereas patient
III-8 needed surgical lens removal and implantation of an artiﬁ-
cial intraocular lens even earlier in his third decade of life be-
cause of congenital cataract. Furthermore, patient III-8 suffered
from spontaneous retinal detachment on the right eye due to a
vitreous degeneration, but vision loss could be prevented by im-
mediate surgical intervention. Patient III-5 exhibited congenital
cataract and iris hypoplasia accompaniedwith transillumination
and intraocular straylight causing moderate photophobia. More-
over, patient III-5 had iridodonesis, mild displacement of the
pupils, slight arcus lipoides and Krukenberg’s spindle pigment
dispersion at the inner corneal surface (Fig. 2A and B).
Novel hemizygous CHRDL1 frameshift mutation results
in a premature termination codon causing reduced
CHRDL1mRNA levels in patient-derived cells
To screen for disease causingmutations in the recently identiﬁed
candidate gene CHRDL1 or possible other unknown X-chromo-
somal candidate genes for megalocornea, a DNA sample of pa-
tient III-5 was analysed by next-generation sequencing after
targeted enrichment of the X-chromosomal exome. This analysis
yielded raw sequence data for the exons of the target region on
X-chromosome comprising 610 kb. 517 kb of this region was cov-
ered by more than 10 reads, and 498 sequence variants were
Figure 1. Family with XMC revealing the intrafamilial phenotypic variability. (A) Index patient (IV-1) with bilateral megalocornea at age of 2 months. (B) Pedigree of the
study family revealing an X-linked inheritance pattern of megalocornea. (C) Corneal diameters of the index patient at age of 14 years (IV-1) and his affected uncle (III-5)
compared with their non-affected brothers (III-3, IV-2). (D) Corneal proﬁles from the lateral view comparing affected males (IV-1, III-5, III-8) with obligate carrier females
(II-2, III-1) and non-affected male relative (IV-2).
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detected with SAMtools. Further ﬁltering of the sequence var-
iants by GeneTalk resulted in seven variants of unknown clinical
signiﬁcance including a hemizygous two basepair deletion
(c.807_808delTC) in exon 9 of the CHRDL1 gene (Fig. 3A). This de-
letion causes a frameshift mutation leading to a substitution of
histidine to tryptophane at codon 270, and a premature termin-
ation codon 22 amino acids downstream (p.H270Wfs*22). We va-
lidated the identiﬁed CHRDL1 mutation by Sanger sequencing
and showed that the allele segregates with the phenotype in
the study family (Fig. 3B) conﬁrming a X-chromosomal recessive
inheritance pattern: the samemutation was detected in all other
affected males (III-8 and IV-1) and in the asymptomatic obligate
carrier females, showing a hemizygous or a heterozygous geno-
type, respectively. Non-affected male siblings did not carry the
CHRDL1 frameshift mutation. We characterized the mutational
effect by reverse transcriptase–polymerase chain reaction (RT–
PCR) analysis of CHRDL1 mRNA extracted from mononuclear
(MNC) and polymorphonuclear (PMN) cells obtained frompatient
III-5 and a control (Fig. 3C) as well as from patient IV-1 and his
healthy brother VI-2 (Supplementary Material, Fig. S1). The mu-
tantCHRDL1mRNAwasmarkedly reduced inMNCand complete-
ly missing in PMN of the patients when compared with healthy
controls.
Knockdown of chrdl1 in Xl recapitulates the human XMC
phenotype and inﬂuences bmp4 expression
To proof that the XMC typical phenotypes are caused by CHRDL1
loss of function, we used the African clawed frogXl as amodel or-
ganism. First, we determined the temporal expression of chrdl1 in
Xl at consecutive developmental stages by RT–PCR. No chrdl1
transcript was traceable at early stages, whereas expression
was detectable at Nieuwkoop and Faber (NF) stage 30 until the
latest stage analysed (NF stage 42; Fig. 4A). This result was corro-
borated by whole mount in situ hybridization (WMISH) with
chrdl1-speciﬁc probes and showed a signal only in late stage em-
bryos (NF stage 37; Fig. 4B). No staining was detectable at earlier
stages (not shown). We observed chrdl1 expression in the optic
cup, the lens and the ciliary marginal zone indicating a speciﬁc
role of CHRDL1 during eye development. In addition, the otic
vesicle, the ependymal layer of the ventricle system and the
notochord were strongly positive for chrdl1 transcript signal.
To induce a chrdl1 loss of function inXenopus, we established a
morpholino (MO) knockdownusing amixture of twodifferentMO
anti-sense oligonucleotides (MO1 + 2) directed against the splice
sites of chrdl1 exon1/intron1 or intron1/exon2. We performed the
MO1 + 2 injection experiments in the 2-cell stage of Xl to reach an
Figure 2.Distinctive phenotypic features of XMC. (A) Slit lamp ﬁndings in affectedmale III-5, indicating ectopia pupillae and congenital cataract (B) as well as the pigment
dispersion (Krukenberg spindle) on the inner corneal surface. Note the cataract of patient III-5 is difﬁcult to see, for better comparison, a cutout photography of the clear
lens of patient IV-1 was added. (C) Deep AC of the eye in patient IV-1 compared with his (D) non-affected brother IV-2. (E) AC and AL of the eyes frompatient IV-1 and III-5
compared with their non-affected brothers (IV-2, III-3) and their mothers (II-2, III-1). (F) Corneal pachymetry of central corneal region (9 mm in diameter) of patient III-5
(right) and his non-affected brother (left). Color code indicates values around 400 µm or beneath in red, and values around 425 µm and above in orange up to blue. (G) HRT
confocal scanning laser ophthalmoscopy of patient IV-1, indicating a normal optical nerve papilla. In the 2D color coded topographymap, neutral null plane is marked in
green, recession up to 0.1 mm in blue, excavation withmore than 0.1 mm in red, also visualized in the proﬁles of orthogonal sections. (H) Comparison of the optical nerve
papilla excavation values of patient IV-1with references according toMooreﬁeld’s classiﬁcation. (I) Non-contact tonometry (mmHg) reveals no elevated IOPof patient IV-1.
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efﬁcient knockdown. As chrdl1 interferes in early developmental
stages with bmp4 and inﬂuences body patterning, we desisted
from rescue experiments by simultaneous chrdl1 overexpression
(10). As shown by RT–PCR analysis (Fig. 5E), the application of
MO1 + 2 efﬁciently repressed chrdl1 splicing in treated embryos.
Figure 5A shows representative photographs of stage 42 embryos.
Phenotypic alterations caused by chrdl1MO1 + 2 injection include
changes of the eye size, mainly enlargement and, in addition,
coloboma (Fig. 5A and B). As indicated, some embryos revealed
pre-bulging of the lens and cornea, similar to the dome-shaped
cornea in XMC patients. Histological sections demonstrated
that Xl, in contrast to the human eye, reveals only a single eye
compartment at least at tadpole stage. This may explain the en-
largement of the whole eye instead of just the anterior part
(Fig. 5C). Interestingly, the pupil and lens of the MO-treated Xl
eye appeared to be slightly ectopic, a feature also observed in
XMC patients with regard to the pupil (Figs 1C and 2A).
From three clutches, 81% of chrdl1 MO1+ 2 injected embryos
showed an alteration of the eye’s structure, compared with 19%
of standard MO-injected controls (total number of embryos
n = 384) (Fig. 5B). Statistical analysis conﬁrmed the correlation
of the eye phenotypes observed with chrdl1 MO1+ 2 injection
(P < 0.001; χ2-test). Next, average eye diameters were measured
and compared between the chrdl1-injected site (is) and the non-in-
jected site (nis) (Fig. 5C andD). Interestingly,we observed a statistic-
ally signiﬁcant increase in the eye’s size when chrdl1 function was
suppressed (P = 0.0028, one-tailed t-test). Wemeasured an increase
in the average eyediameter from477 to 515 μmatNF stage 42 (n= 9).
CHRDL1 interacts with BMP4 in vertebrates (10,13). To investi-
gate the correlation of chrdl1 and bmp4 in the Xl XMC model, we
performed WMISH using a bmp4-speciﬁc probe in chrdl1 MO-
injected embryos (Fig. 6A). Similar to chrdl1, bmp4 is speciﬁcally
expressed in the ocular and periocular regions. Additionally, we
detected strong expression in the otic vesicle and to a broader
extent in the ventricular zone of the forebrain. In contrast to
the chrdl1, the lens expresses bmp4 at a much lower level. Bmp4
expression appears to be reduced on the chrdl1 MO-injected
side, especially in the ventral ocular and periocular region as
well as in the otic vesicle (Fig. 6B).
Altered BMP signaling in association with CHRDL1
mutation
To determinewhether the CHRDL1mutation of our XMC patients
inﬂuences the BMP pathway, intracellular phospho-SMAD1/5
was quantiﬁed in lymphoblastoid cell lines (LCLs) byﬂow cytometry
Figure 3.Novel CHRDL1 frameshift mutation resulting in reducedmRNA levels. (A) Overview of previously described CHRDL1mutations and alignment of sequence reads
after X-chromosomal exome sequencing by IGV browser. Depicted is a part of the CHRDL1 locus Xq23. Boxes indicatemagniﬁcations of CHRDL1 exon 9 that harbors the 2-
base pair deletion. Note that CHRDL1 is located on the reverse strand of the X-chromosome; therefore, the reverse complement sequence is shown. (B) Representative
results of segregation analysis by Sanger sequencing of CHRDL1 exon 9 in the study family, showing hemizygous, heterozygous or wild-type genotype for affected
males, asymptomatic carrier females or non-affectedmales, respectively. (C) Semi-quantitative RT–PCR analysis of CHRDL1mRNA levels in affectedmale III-5 and control.
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as functional read-out for BMP signaling activity. Under unstimu-
lated conditions, we measured a slightly higher level of intracel-
lular phospho-SMAD1/5 in LCLs of patient IV-1 (ΔMFI: 133) when
compared with LCLs obtained from his healthy brother VI-2
(ΔMFI: 81) (Fig. 7A). In contrast, BMP2/4 stimulation caused an in-
creased phospho-SMAD1/5 induction in LCLs from the healthy
brother IV-2 (ΔMFI: 534) compared with LCLs from patient IV-1
(ΔMFI: 300) (Fig. 7B). This correlates with less abundance of BMP
receptor 1A (BMPR1A) on the cellular surface (Fig. 7C) as well as
in the intracellular compartment (Fig. 7D) of LCLs from patient
IV-1 (ΔMFI: 19 and ΔMFI: 5510, respectively) compared with LCLs
from his healthy brother IV-2 (ΔMFI: 62 and ΔMFI: 7422).
CHRDL1 (Ventroptin) is expressed like a limbal stem cell
niche factor in adult human cornea
Immunohistochemistry of the CHRDL1-encoded protein andBMP4
on healthy human cornea samples from anatomical sections re-
vealed an almost mutual exclusive pattern of CHRDL1 and BMP4
proteins, especially in the corneal epithelium (Fig. 8A). Although
BMP4 is uniformly distributed over the whole corneal epithelium,
CHRDL1 is markedly expressed in the basal epithelium with a
high–low expression gradient from the limbal stem cell niche to
the mid corneal region. Additionally, the CHRDL1 protein signal
is enhanced in stromal keratocytes of the limbuswith fading levels
centripetally. In contrast, BMP4 is expressed to a lesser extent in
corneal stroma. Both proteins are strongly expressed in the
corneal endothelium as well.
Discussion
Based on the ﬁnding of a novel CHRDL1 frameshift mutation in a
large family with XMC, we initiated a comprehensive investiga-
tion to understand themolecular mechanism. By clinical assess-
ment and segregation analysis, we show that the CHRDL1
mutation is fully penetrant, but the broad intrafamilial pheno-
typic variability is challenging with respect to an appropriate
medical management and prognostic estimation: ﬁrst, clinical
signs of XMC can be overlooked in newborns or be misdiagnosed
as primary congenital glaucoma, leading to unnecessary sed-
ation for the IOPmeasurement. Second, the severity of biometric
abnormalities does not correlate with congenital cataract or pig-
ment dispersion. Third, spontaneous retinal detachment due to
vitreous degeneration has to be considered (14). Therefore, a ro-
bust genetic testing is important for early diagnosis and adequate
patient care (Table 1).
The identiﬁed CHRDL1mutation in our study family conﬁrms
the homogeneous genetic origin of XMC (3,8,9). It emphasizes the
pathomechanistic role of the TGFβ signaling, which has also been
found in connective tissue disorders associated with megalocor-
nea, e.g. Marfan syndrome (5). The autosomal-recessive type of
megalocornea with marfanoid habitus and zonular weakness
[MIM251750], caused by genetic alterations in the Latent trans-
forming growth factor-beta-binding protein 2 (LTBP2) [MIM602091],
is associated with the same pathway (15,16).
The CHRDL1 frameshiftmutation in our patients leads to a pre-
mature stop codon presumably resulting in decreased CHRDL1
mRNA levels. One frequently used mechanism to abolish
Figure 4. Chrdl1 expression in Xl displays a phylogenetic conserved function for eye development. (A) Temporal RT–PCR analysis of chrdl1 expression (top panel); different
developmental stages indicated at the top. Odc functions as RNA input control (bottom). (B) Spatial analysis of chrdl1 expression. Whole mount in situ hybridization
(WMISH) of wild-type Xl embryos at NF stage 37 (top panel) and corresponding sections (bottom panel). Expression of chrdl1 in the lens (white star), the optic cup
(black arrows), the otic vesicle (blue arrow), the ependymal layer of the ventricle system (yellow arrow) and the notochord (red arrow).
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non-functional mRNA molecules is nonsense-mediated RNA
decay (NMD) (17,18). Indeed, we measure complete loss of
CHRDL1 mRNA in PMN cells and mRNA reduction in MNC cells.
Therefore, as reported for most XMC-associated CHRDL1 muta-
tions, we assume a CHRDL1 loss of function as the underlyingmo-
lecularmechanism.On theonehand, cell type-speciﬁc differences
in NMD efﬁciency are known (18), which could explain the differ-
ent degrees of CHRDL1mRNA reduction observed in different cells
of our patients. On the other hand, the known CHRDL1 transcripts
could differ in their stability, since they vary in their 3′UTRor pos-
sibly in their transcriptional rate depending on cell type. The
abundance of different transcripts in the cell types could also ex-
plain the difference in the level of CHRDL1 mRNA reduction. In
MNCs, the resulting truncated protein, containing only two of
the three cysteine-rich highly conserved von Willebrand factor,
type C domains (VWFC), with BMP binding afﬁnity, should have
a reduced antagonistic effect on BMP4. So far, 13 from 19 currently
described CHRDL1mutations cluster to the VWFC domains. Most
of them lead to premature stop codons at the beginning of the cod-
ing sequenceand should effectively benullmutationsdue toNMD
(3). Twowhole gene deletions support the assumedCHRDL1 loss of
function mechanism in XMC. Regarding the broad phenotypic
variability of XMC, even in an intrafamilial setting, an interfamilial
genotype–phenotype correlation with respect to ocular and most
probably subclinical non-ocular organ manifestations is quite
challenging and remains to be elucidated. It is not yet fully under-
stood how CHRDL1 mutations can cause an eye-speciﬁc pheno-
type, although it is widely expressed in different tissues
(9,10,13,19). Among others, the functional outcome of the muta-
tion (loss versus gain of function), the co-expression with redun-
dant BMP antagonists (e.g. CHRD) in certain tissues and the
above-mentioned cell type-dependent NMD efﬁciency or RNA
stability should play an important role in the organ-speciﬁc
manifestation.
According to the currently prevailingmodel, cornea growth is
achieved by differentiation of limbal stem cells during eye devel-
opment (20,21). Therefore, we postulate that XMC results from
premature cornea development due to accelerated growth and
differentiation of limbal stem cells by an imbalanced CHRDL1-
BMP4 antagonism in favor of BMP signaling and vice versa in
Figure 5.Knockdown of Chrdl1 in Xl recapitulates the humanXMC phenotype. (A) Phenotype ofXl embryos injectedwith amixture of chrdl1MOs (MO1 + 2) or standardMO
into one blastomere of 2-cell stage embryos grown toNF stage 42. is, injected side; nis, non-injected side; Strd, standard. green arrow, coloboma; red arrow, pre-bulged lens.
Xl can differ in skin pigmentation. (B) Respective phenotypes are quantiﬁed and presented as a bar graph in percent (%) (black, phenotype; white, no pathological
phenotype); double asterisk indicate the statistical signiﬁcance calculated by the χ2 test. Phenotype subgroups are presented as a pie chart (right); for phenotypic
subgroups of standard MO, see Supplementary Material, Figure S2. (C) Histomorphological and biometrical acquisition of Xl eyes. Shown are plan view magniﬁcations
of injected versus non-injected eyes with two diameters (measured orthogonal to each other). (D) Bar graphs of the average eye diameter (μm) with statistical analysis
(one-tailed t-test). (E) Semi-quantitative RT–PCR analysis measuring the MOs MO1 + 2 induced chrdl1 knockdown efﬁciency.
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the case ofmicrocornea (Fig. 8B). Consistentwith this hypothesis,
BMP4 loss of function is known to cause microcornea in the form
of syndromicmicrophtalmia type 6 (MCOPS6;MIM607932) (22,23).
To proof our hypothesis, we established the ﬁrst in vivo XMC
model using a knockdown approach inXl. Until now, only the im-
pact of chrdl1 overexpression was tested on Xl development.
These results demonstrate that chrdl1 similar to chordin is able
to induce secondary axis formation after mRNA injection (10).
We show that the suppression of chrdl1 function induces eye phe-
notypes in the Xenopus tadpole that resemble the human XMC
phenotype, i.e. larger eyes with speciﬁc ﬁndings in the anterior
eye segment. Together with the spatiotemporal expression of
chrdl1 at tadpole stages, we give compelling evidence that chrdl1
plays a conserved role during eye development. We therefore
speculate that chrdl1 knockdown in Xl induces accelerated ocular
growth. Our additional ﬁnding of pathologically widened colo-
boma has not previously been reported for the phenotypic spec-
trum of XMC. Thus, we propose that CHRDL1 gene analysis
should be considered for patientswith iris coloboma. Interesting-
ly, themild ectopic pupils observed inXMCpatients can be the re-
sult of a mild variant of iris ﬁssure closure. This observation is
consistent with the association between coloboma and loss of
function of Smoc1 (SPARC-related modular calcium binding 1),
another BMP antagonist, in gene-trap mice (24). Furthermore,
we observe a difference between chrdl1 and bmp4 expression le-
vels in the lens of Xl. We speculate that CHRDL1 physiologically
prevents the development of cataract by preserving either a
metabolic or structural homeostasis to maintain the transpar-
ency of the lens. Additionally, we are the ﬁrst to report on
chrdl1 expression in the otic vesicle and the ependymal layer of
the cerebral ventricular system. A possible clinical relevance of
these ﬁndings remains to be elucidated in XMC patients.
The establishment and preservation of stable developmental
gradients appears to requiremultiplemechanisms to balance ag-
onistic and antagonist effects on BMP signaling. Consistent with
this theory, we observe a down-regulation of bmp4 expression
caused by chrdl1 knockdown. This implies that an overactive
Bmp signaling due to the deﬁcient antagonist is additionally con-
trolled on the transcriptional level by a negative feedback mech-
anism (25,26).Moreover, using intracellular phospho-SMAD1/5 as
functional BMP signaling read-out, we measure paradoxical and
obviously pathological effects in association with the here re-
ported CHRDL1mutation. On the one side, the basal BMP signal-
ing activity is elevated comparing XMC versus healthy state. On
the other hand, the BMP signaling is less inducible in correlation
with lower superﬁcial and intracellular BMPR1A abundance
Figure 6. Chrdl1 knockdown inﬂuences bmp4 expression in Xl. (A) Chrdl1 MOs MO1 + 2-injected embryos (NF stage 37) were used for in situ hybridization with bmp4 as a
marker probe. is, injected side; nis, non-injected side. Expression of bmp4 in the optic cup (red arrows), the otic vesicle (green arrow) and the ependymal layer of the
ventricle system (yellow arrow) in the embryo (A) and its corresponding sections (B).
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comparing lymphoblastoid cells from XMC patient versus
healthy brother. Together, we assume that the higher BMP sig-
naling baseline in our XMC patient is the result from a failing
BMP antagonism and consequently increased binding of BMP to
BMPR1A. This induces a negative-feedback mechanism and
leads to a compensatory down-regulation of BMP receptors (26).
We assume that this kind of negative-feedback regulation
modiﬁes the mutational outcome in a cell-dependent manner
and can also be a reason for organ-speciﬁc manifestations and
phenotypic variability.
Finally, the protein distribution pattern in our adult human
cornea studies suggests that the developmentally important
CHRDL1-BMP4 antagonism could play a role in postnatal homeo-
stasis of the cornea.We speculate that CHRDL1 acts as a stem cell
Figure 7. BMP signaling is altered in association with reported CHRDL1 mutation. BMP signaling was analyzed in lymphoblastoid cell lines of XMC patient IV-1 and his
healthy brother IV-2 by ﬂow-cytometry. Unprocessed MFIs are given for each speciﬁc staining and background measurement. (A) Basal level of intracellular pSMAD1/
5. One representative experiment out of three is shown. (B) BMP-induced intracellular pSMAD1/5. One representative experiment out of three is shown. (C) Surface
and (D) intracellular staining of BMPR1A. One representative experiment out of two is shown.
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niche factor by attenuating the BMP4-mediated growth and dif-
ferentiation, thereby preventing the exhaustion of the limbal
stem cell pool. A similar role has been postulated for CHRDL1 in
the intestinal stem cell niche (19). This concept is additionally
supported by in vitro studies showing that the application of
recombinant CHRDL1 inhibits differentiation and/or enhances
proliferation of human mesenchymal stem cells and osteoblast
precursor cell lines (25). Moreover, CHRDL1-mediated repression
of BMP signaling leads to reactivation of embryonic homeobox
genes like MSX1 in immature lymphoblastic leukemia cells
(T-ALL) (27,28).
In the case of superﬁcial lesions, FGF2 signaling regulates the
reconstitution of the cornea layers without ﬁbrosis, while deep
lesions lead to the activation of TGFβ/BMP signaling in stromal
keratocytes resulting in ﬁbrosis (29). The increased expression
of CHRDL1 in the stromal keratocytes of the corneal limbus sug-
gests that CHRDL1 is also involved in repair mechanisms of the
cornea.
Here, we propose a model, in which CHRDL1 inﬂuences BMP4
signaling to prevent ﬁbrosis and limbal stem cell insufﬁciency,
the latter often accompanied with irreversible lesions of the cor-
nea. We suggest that CHRDL1 is a limbal stem cell niche factor
and therefore an attractive target for regenerative medical ther-
apies of corneal injuries.
Materials and Methods
Human and animal research
All subjects or their legal representatives gave written informed
consent to the study, which was performed in accordance with
the Declaration of Helsinki. The informed-consent protocol for
diagnostic genetic testing complies with the regulations of the
German law for gene diagnostics (Gen-Diagnostik Gesetz).
Cornea tissue samples were obtained from human anatomical
sections performed at the Kantonsspital Basel (Switzerland) in
accordance with the local ethics committee. All animal research
procedures were performed according to guidelines set by the
German animal use and care laws (Tierschutzgesetz) and
approved by the German state administration Saxony-Anhalt
(Projekt/AZ: 42502-3-600 MLU).
Ophthalmic examination
An ophthalmologist (P.R.) clinically assessed patients and their
family members. Standard evaluation consisted of assessment of
refraction anomalies and photographic documentation including
scale-adjusted corneal diameter measurement, lateral view cor-
neal proﬁle and slit lamp ﬁndings. Measurement of the axial eye
length and the AC depth was performed by optical interferometry
(IOLMaster, Carl Zeiss Meditec). For corneal pachymetry, the Dual
Scheimpﬂug Analyzer (Galilei) was used. Glaucoma in patients
and their relatives were excluded by non-contact tonometry,
stereoscopic evaluation of the optic nerve and confocal scanning
laser ophthalmoscopy (HRT, Heidelberg Engineering) (30).
X-chromosomal exome capture and next-generation
sequencing
Genomic DNA samples from the patients were extracted from
ethylenediaminetetraacetic acid (EDTA) peripheral blood sam-
ples. We enriched the X-chromosomal exome from 4 µg DNA of
Figure 8. Protein expression of CHRDL1 and BMP4 in adult human cornea underlines their antagonistic function. (A) Immunohistochemistry of CHRDL1 (blue) and BMP4
(red) in healthy human cornea from anatomical sections. CHRDL1 is present in basal epithelial cells and stromal keratocytes of the limbus with decreasing protein levels
centripetally. In contrast, BMP4 is homogeneously present in corneal epithelium and to a lesser extent in corneal stroma (bottom). Both proteins are also expressed in
endothelium. Hematoxylin was used for counterstaining. (B) Model of molecular pathomechanism of megalocornea during late embryonic development of the
anterior eye segment.
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patient III-5 using the Agilent SureSelect enrichment Kit accord-
ing to the manufacturer’s instructions. Single reads with a read
length of 76 nucleotides were obtained by next-generation se-
quencing of one sample per lane with a mean coverage >30-
fold on the Illumina Genome Analyzer IIx. The raw sequence
data were aligned to the NCBI37/hg19 assembly of the human
genome by Novoalign (31). Sequence variants were called by
SAMtools and analyzed for an X-linked recessive inheritance
mode using GeneTalk (32,33). Sequence variants with an allele
frequency above 0.1% in healthy controls were removed and re-
duced to alleles with a predicted effect on the protein level (mis-
sense, stop-gain, stop-loss, frameshift, non-frameshift, splicing).
Validation of CHRDL1mutation by Sanger sequencing
PCR ampliﬁcation and bidirectional sequencing of the identiﬁed
CHRDL1 mutation were performed using exon 9 forward 5′-CCA
TGG CTA TGA CAA GAA CAA A-3′ and reverse 5′-TCT TCC AAG
CAACTG CCT TT-3′ primers according to the standard protocols.
The sequence analysis was performed on an ABI3130xl capillary
sequencer (Applied Biosystems). Sequence data were processed
using ABI software and were analyzed using Sequence Pilot (JSI
medical systems GmbH) based on the complementary DNA
(cDNA) reference sequence for CHRDL1 (NM_001143981; ENST00
000372042). The identiﬁed mutation was submitted to the public
database ClinVar http://www.ncbi.nlm.nih.gov/clinvar/ (ClinVar-
Accession SCV000195644, date last accessed, 20 February 2015).
Semi-quantitative RT–PCR
Peripheral blood samples were fractionated into MNC cells and
granulocytes using the Ficoll-based standard protocol. RNA ex-
traction was performed after cell lysis with TRIzol reagent (Invi-
trogen, Carlsbad, CA, USA) according to the phenol-chloroform
standard protocol. Approximately 500 ng of RNA was extracted
and reversely transcribed into cDNA with oligo-dT primers
usingMMLVRT (Life Technologies, USA). TheCHRDL1 exon-span-
ning PCRwas performedwith exon 2 forward primer 5′-AAGGAG
GCAAAAACAGAG CAA-3′and exon 3 reverse primer 5′-AAC CAA
CCC ATA AGG TTC CA-3′. The PCR products were visualized by
Table 1. Comparison of etiology, phenotypes, management and prognosis of different disorders affecting cornea biometry
Differential
diagnosis: altered
corneal biometry
XMC/anterior
megalophthalmos/
megalocornea 1
[MIM309300] (1, 2,9)
Megalocornea with
microspherophakia [MIM251750]
allelic to primary congenital
glaucoma 3D [MIM613086] (15,16)
Primary congenital
glaucoma 3A [MIM231300]/
open angle glaucoma 1A
[MIM137750] (39–41)
Keratoconus
[MIM148300]/
keratoconus with
cataract [MIM614303]
(42–44)
Disease gene CHRDL1 LTBP2 CYP1B1, MYOC VSX1, miR-184
Locus Xq23 14q24.3 2p22.2, 1q24.3 20p11.21, 15q25.1
Inheritance X-chromosomal recessive Autosomal recessive Autosomal recessive/
dominant
Autosomal dominant
Diagnostic ﬁndings
Corneal
diameter
>12.5 mm >12.5 mm >12.5 mm (asymmetrical) <12.5 mm
Corneal proﬁle Dome-shaped Flat Dome-shaped Cone-shaped
AC Deep Deep/Flat Deep Normal
Pigment
dispersion
Krukenberg spindle Unknown Sporadically present Unknown
Lens shape Normal Spherophakia Normal Normal
Iris/ciliary ring Enlarged + zonular
weakness
Enlarged + zonular weakness Primarily normal Primarily normal
IOP Primarily normal Elevated in the case of lens
dislocation
Primarily elevated Primarily normal
Optic nerve
cupping
Primarily normal Primarily normal Excavated Normal
Medical implications
Refraction
anomalies
Mild myopia/astigmatism Mild myopia/astigmatism Primarily normal Severe myopia/
astigmatism
Lens luxation Elevated risk Highly elevated risk No luxation No luxation
Lens haze Congenital cataract Unknown Unknown Unknown
Corneal
opaciﬁcation
Mosaic corneal
degeneration
Unknown Descement-related Unknown
Retinal
detachment
Axial eye length-related Unknown Unknown Unknown
Medical management
Surgery Electively: trabeculotomy,
cataract surgery,
keratoplasty
Electively/instantly: lens removal Instantly: goniotomy Contact lenses, cross-
linking, electively
keratoplasty
Follow-up Regularly, long-term
complication adjusted
Short intervals, short-term
complication adjusted
Short intervals, short-term
complication adjusted
Regularly, mid-term
complication
adjusted
Prognosis Low to middle risk for
vision impairment
Middle to high risk for vision
impairment
Middle to high risk for
vision impairment
Low to middle risk for
vision impairment
Human Molecular Genetics, 2015, Vol. 24, No. 11 | 3129
running a 2% agarose gel with a mix molecular weight marker
(NEB), stainingwith ethidiumbromide and photo documentation
under an UV transilluminator.
LCL culture and treatment with BMPs
Lymphoblastoid cell lines were generated from peripheral blood
MNC cells according to a previously described protocol (34). LCLs
from XMC patient IV-1 and his healthy brother IV-2 were kept in
the Roswell Park Memorial Insitute medium supplemented with
10% fetal calf serum (FCS), 1% penicillin/streptomycin and 1%
glutamine. Stimulation with 125 ng/ml recombinant human
BMP2 (355-BM-010, R&D Systems, Germany) or 100 ng/ml recom-
binant human BMP4 (314-BP-010, R&D Systems, Germany) was
performed on 5 × 105 LCLs /well in 24-well plates for 24 h.
Flow cytometry
Flow cytometric analyses for surface receptor expression on live
cells and for intracellular components on ﬁxed/permeabilized
cells were essentially performed as recently described (35). Brief-
ly, 1 × 105 cells were stained with speciﬁc antibodies in ﬂuores-
cence-activated cell sorting (FACS) buffer [phosphate-buffered
saline (PBS) with 1% FCS and 0.3 m EDTA]. Prior to speciﬁc anti-
body staining with anti-BMPR1A (ab38560, abcam, UK) and sec-
ondary anti-rabbit IgG-Alexa488 (A-11034, Invitrogen) on live
cells, treatment with Fcγ block for 10 min on ice was performed.
For live cell analyses, dead cells were excluded using PI staining.
For intracellular analyses, cells were ﬁxed for 10 min at 37°C with
4% paraformaldehyde. Followed by twowashing steps, cells were
permeabilized with 90% methanol buffer for 30 min on ice. Prior
to speciﬁc antibody staining with anti-phospho-SMAD1/5
(Ser463/465) (13820P, Cell Signaling, USA) and anti-rabbit IgG-
Alexa488 in FACS buffer, cells were incubated with Fcγ block for
15 min. Flow cytometry was performed using LSR FortessaTM
(Becton Dickinson) ﬂow cytometer and FACS-DivaTM and Flow-
JoTM (Tree Star) software. To compare the protein levels between
individuals, we calculated delta mean ﬂuorescence intensities ΔMFI,
meaning the subtraction of background MFI from speciﬁc MFI.
Immunohistochemistry
To investigate the physiological protein expression pattern of
CHRDL1 (Ventroptin) and BMP4 in the human anterior eye seg-
ment, parafﬁn-embedded ophthalmic tissues were analyzed by
immunostaining. We used a polyclonal rabbit anti-CHRDL1 anti-
body (HPA000250, ATLAS, Sweden) and a polyclonal rabbit anti-
BMP4 antibody (ab39973, abcam) diluted 1:2000, respectively.
Secondary Biotin-labeled anti-rabbit antibodies as diluted by
the manufacturer (KPL, USA) were incubated and detected by
Streptavidin-conjugated horseradish peroxidase using True-
BlueTM (CHRDL1) or Vectorred (BMP4) as a substrate.
Organisms and maintenance
Frogs (Xl) were obtained from commercial suppliers (NASCO,
USA). Production and rearing of embryos was performed as de-
scribed previously (36) and embryos were maintained at 15°C
and staged according to NF.
Xl histology
For the preparation of vibratome sections, stained and ﬁxed
embryos were equilibrated in PBS containing 4.4 mg/ml gelatin,
0.27 g/ml bovine serum albumin and 0.18 g/ml sucrose. After
equilibration, embryos were mounted by cross-linking the solu-
tion with glutaraldehyde. 30 μm sections were obtained with a
Vibratome andmounted onto gelatin-coated slides. Photographs
were taken on a Zeiss Imager M1 using Nomarski interference
optics.
WMISH and RT–PCR
To analyze the spatiotemporal expression of chrdl1 during Xl em-
bryogenesis, a DIG-labeled ‘antisense’ RNA probe was generated
by linearizing with Hind3-HF (NEB) and in vitro transcription with
T7 RNA polymerase (Roche) as described before (37). Xenopus
embryos were ﬁxed at different developmental stages and
whole-mount in situ hybridization was carried out as described
previously (38). Embryos probed with antisense RNAs of chrdl1
were vibratome sectioned (30 μm) and photographed. RT–PCR
was performed with the following intron spanning primers to
amplify both possible chrdl1 transcript variants scaffold71612
and scaffold10201, as annotated in Xenbase: chrdl1fwd-RT 5′-
CTA GAG CCC TAT GGC CTT G-3′, chrdl1rev-RT 5′-TGG TTC GTG
ATG CTC CCA G-3′, odcfwd-RT 5′-GCC ATT GTG AAG ACT CTC
TCC ATT C-3′, odcrev-RT 5-TTC GGG TGA TTC CTT GCC AC-3′.
Xl knockdown experiments
25-mer MOs (Gene Tools, LLC Philomath, Oregon) were designed
to target the splice site between Exon1 and Intron1 (MO1: 5′-ATC
GAA ATG ATA TTA CCT CTC GGC A-3′) or between Intron1 and
Exon2 (MO2: 5′-CCA CCC TGA AAG ATA AAT CTC ACA T-3′) in
chrdl1 mRNA transcripts. A mismatch standard MO was used as
control (5′-CCTCTTACCTCAGTTACAATTTATA-3′). Tomeasure
the silencing efﬁciency by RT–PCR (see the above-mentioned pri-
mer pair), 2.5 pmol of either the chrdl1MO1 + 2 mixture or stand-
ard MO was injected into both blastomeres of 2-cell stage
embryos, grown and collected at NF-stage 42. For unilateral
knockdown experiments, we injected either the chrdl1 MO1 + 2
mixture or the standard MO into one blastomere of 2-cell stage
embryos. For statistical analysis of the differing eye phenotype
between both injection categories, we used the χ2 test including
a total number of 384 embryos from three independent clutches.
For biometric comparison of individual Xl eyes (injected side
versus non-injected side), we calculated the mean value of both
indicated diameters that are orthogonal to each other. We imple-
mented the mean values of nine animals for statistical analysis
using the one-tailed t-test.
Supplementary Material
Supplementary Material is available at HMG online.
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